MoonLake Immunotherapeutics (MLTX) — Net Asset Quality Index
MoonLake Immunotherapeutics (MLTX) has a Net Asset Quality Index of 71.7% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $424.43 Million minus total liabilities of $119.95 Million yields net assets of $304.48 Million. A higher index indicates a stronger, lower-leverage balance sheet. See MLTX defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
MoonLake Immunotherapeutics Net Asset Quality Index Over Time (2020–2025)
This chart shows how MoonLake Immunotherapeutics's Net Asset Quality Index has evolved across 6 annual periods from 2020 to 2025. As of December 2025, the index stands at 71.7%, representing net assets of $304.48 Million against total assets of $424.43 Million USD. Explore cash efficiency ratio of MoonLake Immunotherapeutics to assess how effectively this company generates cash.
Annual Net Asset Quality Index for MoonLake Immunotherapeutics (2020–2025)
The table below presents the year-by-year Net Asset Quality Index for MoonLake Immunotherapeutics from 2020 to 2025, covering 6 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market cap of MoonLake Immunotherapeutics.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 71.7% | $304.48 Million | $424.43 Million | $119.95 Million | ▼ -23.1 pp |
| 2024 | 94.9% | $453.39 Million | $477.93 Million | $24.54 Million | ▼ -2.7 pp |
| 2023 | 97.5% | $513.49 Million | $526.54 Million | $13.05 Million | ▲ +8.0 pp |
| 2022 | 89.5% | $68.77 Million | $76.84 Million | $8.08 Million | ▲ +209.8 pp |
| 2021 | -120.3% | $-11.65 Million | $9.68 Million | $21.33 Million | ▼ -216.7 pp |
| 2020 | 96.4% | $112.48 Million | $116.63 Million | $4.15 Million | — |